TriNav Infusion System for the Evaluation of Fidelity Between 99mTc-MAA and Y90-Microspheres Hepatic Distribution for Dosimetry Treatment Planning
Sponsor: M.D. Anderson Cancer Center
This NA trial investigates Liver Cancer and is currently ongoing. M.D. Anderson Cancer Center leads this study, which shows 12 recorded versions since 2023 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Mar 2026 — Present [monthly]
Active Not Recruiting NA
-
Oct 2025 — Mar 2026 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
May 2025 — Oct 2025 [monthly]
Recruiting NA
-
Apr 2025 — May 2025 [monthly]
Recruiting NA
-
Oct 2024 — Apr 2025 [monthly]
Recruiting NA
Status: Active Not Recruiting → Recruiting
▶ Show 7 earlier versions
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting NA
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Recruiting NA
-
May 2024 — Jul 2024 [monthly]
Recruiting NA
-
Oct 2023 — May 2024 [monthly]
Recruiting NA
-
Apr 2023 — Oct 2023 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Mar 2023 — Apr 2023 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- M.D. Anderson Cancer Center
- TriSalus Life Sciences, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .